About the Belfer Institute
The Belfer Institute for Applied Cancer Science is a fully integrated, collaborative cancer research center dedicated to translating today’s most innovative oncology research into tomorrow’s most promising cancer treatments. This highly focused, goal-oriented organization represents a new academic construct that embeds an industrial approach within a premier academic setting. The Institute’s excellence in leading edge early-stage biology enables its scientists to define the best targets and the optimal clinical path for targeted cancer therapies. The Belfer Institute’s strategic collaborations with leading pharmaceutical companies are driving the development of a next generation of cancer therapies. The Belfer Institute is part of the Dana-Farber Cancer Institute and is affiliated with Harvard Medical School.
In the News
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.